Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

PHASE3TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Growth Hormone Deficiency (GHD)
Interventions
DRUG

Saizen®

Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.

Trial Locations (1)

Unknown

US Medical Information

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT01237340 - Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study | Biotech Hunter | Biotech Hunter